ViennaLab Diagnostics GmbH

Evaluate the response to monoclonal antibody-mediated cancer therapies by Fc gamma receptor genotyping.

Germline polymorphisms in the Fc gamma receptor (FCGR) gene have been reported to influence antibody-based cancer therapies. The FCGR StripAssay® identifies the variants FCGR2A-H131R and FCGR3A-F158V.




  • Enhanced response to monoclonal antibody-mediated cancer therapies has been reported in several studies in patients carrying the higher-affinity FCGR2A-131His (rs1801274) or FCGR3A-158Val (rs396991) alleles.
  • In colorectal cancer 56% of patients with FCGR3A-158 F/F genotype responded to treatment with cetuximab and bevacizumab, compared to 25% with heterozygous F/V and 8% with homozygous V/V genotype. Zhang et al., Anticancer Res. 2010 Oct;30(10):4209-17.
  • Breast cancer patients with the genotypes FCGR2A-131 H/H and FCGR3A-158V/V responded favourably to trastuzumab therapy. Musolino et al., J Clin Oncol. 2008 Apr 10;26(11):1789-96.
  • Although there is rising evidence that FCGR genotyping may help in treatment stratification, some studies show diverging results. Recommendations using FCGR polymorphisms for treatment decissions are currently not available. For a review see: Nagelkerke et al., Front Immunol. 2019 Oct 3;10:2237.


ProductReg. Stat.REFUnit SizeIFUBrochure
FCGR StripAssay® RUO5-67020 tests


We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.